- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Biocon Receives EU GMP Certification
Biocon’s biologics facilities in Bengaluru, India, have received an EU certification of good manufacturing practice (GMP) after a March 2019 inspection, said the drug maker last week in a notice to the National Stock Exchange of India.
Biocon’s biologics facilities in Bengaluru, India, have received an EU certification of good manufacturing practice (GMP) after a March 2019 inspection, said the drug maker last week in a notice to the National Stock Exchange of India.
A company spokesperson said in an email to The Center for Biosimilars® that “This was a surveillance inspection of our existing [drug product, DP] and [drug substance] facilities and a preapproval inspection of our additional DP manufacturing line. This certification will enable us to continue addressing the growing needs of patients in the EU markets and enhance access to our high-quality biosimilars.”
The Bengaluru facility is the site where Biocon manufactures its portfolio of biosimilar products, including the biosimilar products on which the company partners with fellow drug maker Mylan. The partnership is responsible for such FDA-approved biosimilars as Fulphila, a pegfilgrastim biosimilar that is already available in the US market, and Ogivri, a trastuzumab biosimilar expected to launch in 2019.
The Biocon and Mylan partnership also includes in-licensed adalimumab and etanercept products in the European marketplace, as well as several insulin biosimilars in various stages of development.
Biocon has also entered into a partnership with another biosimilar developer, Sandoz, for the development, manufacture, and commercialization of multiple, as yet undisclosed biosimilars targeting immunology and oncology indications.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
